Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 15/20 | 0.73 |
| ▸ | CDK5R1 | Q15078 | 15/20 | 0.73 |
| ▸ | CCNA2 | P20248 | 14/20 | 0.73 |
| ▸ | CDK2 | P24941 | 14/20 | 0.73 |
| ▸ | CCNA1 | P78396 | 14/20 | 0.73 |
| ▸ | DYRK1A | Q13627 | 13/20 | 0.73 |
| ▸ | CDK1 | P06493 | 7/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.73 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.73 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.73 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.73 |
| ▸ | INSR | P06213 | 2/20 | 0.73 |
| ▸ | PRKACA | P17612 | 2/20 | 0.73 |
| ▸ | PRKACG | P22612 | 2/20 | 0.73 |
| ▸ | PRKACB | P22694 | 2/20 | 0.73 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.73 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490493 | 1.00 | CDK5 (0.73) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL4559411 | 0.89 | CDK5 (0.74) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL4559413 | 0.89 | CDK5 (0.74) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| Purvalanola SCHEMBL3311119 | 0.85 | CDK5 (1.00) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| Purvalanola SCHEMBL1217069 | 0.85 | CDK5 (1.00) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| Purvalanola SCHEMBL30375366 | 0.85 | CDK5 (1.00) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| Purvalanola SCHEMBL29360281 | 0.85 | CDK5 (1.00) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL13638193 | 0.84 | CDK5 (0.76) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL4489273 | 0.81 | CDK5 (0.66) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL20694113 | 0.78 | CDK5 (0.77) | CDK5CDK5R1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612079-B2 | 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612079-B2 | 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| EP-1399446-B1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LTD (GB) | 2005-08-03 | — | — | EP | disclosed |
| US-20050009846-A1 | 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009846-A1 | 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders | TYMP, PNP, IMPDH1 | CDK5 83/4885CDK5R1 107/4885CCNA2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.